ResearcherNational Institutes of HealthActive in the last 2 years
Murali Cherukuri Krishna
Matched on ORCID iD 0000-0002-7216-7788; OpenAlex author ID A5108423916; NIH RePORTER profile ID 15686910. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 4)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 11
2019: 1 paper · 2020: 2 papers · 2021: 1 paper, 1 grant · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper, 1 grant
Papers 7
- Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated prodrug. Co-author DOI 10.1016/j.freeradbiomed.2024.07.008↗
- Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination… Co-author DOI 10.1089/ars.2022.0118↗
- PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Co-author DOI 10.1016/j.neo.2022.100793↗
- Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy. Last author DOI 10.1089/ars.2020.8131↗
- Reoxygenation after Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts is due to Decreased Oxygen Consumption and not Increased Oxygen Supply Last author DOI 10.1101/2020.05.16.099853↗
- Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenoca… Last author DOI 10.1158/0008-5472.can-19-0928↗
- Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. Last author DOI 10.7554/elife.46312↗
Grants 2
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- murali cherukuri · 2 shared grants, 2021–2024 · strength 1.47
- Jeffrey Brender · 7 shared papers, 2019–2024 · strength 0.99
- Paper Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated p… DOI 10.1016/j.freeradbiomed.2024.07.008↗
- Paper Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature an… DOI 10.1089/ars.2022.0118↗
- Paper Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox … DOI 10.1089/ars.2020.8131↗
- Kazutoshi Yamamoto · 7 shared papers, 2019–2024 · strength 0.99
- Paper Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated p… DOI 10.1016/j.freeradbiomed.2024.07.008↗
- Paper Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature an… DOI 10.1089/ars.2022.0118↗
- Paper Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox … DOI 10.1089/ars.2020.8131↗
- Shun Kishimoto · 7 shared papers, 2019–2024 · strength 0.99
- Paper Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated p… DOI 10.1016/j.freeradbiomed.2024.07.008↗
- Paper Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature an… DOI 10.1089/ars.2022.0118↗
- Paper Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox … DOI 10.1089/ars.2020.8131↗
- James B. Mitchell · 6 shared papers, 2019–2023 · strength 0.78
- Paper Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature an… DOI 10.1089/ars.2022.0118↗
- Paper Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox … DOI 10.1089/ars.2020.8131↗
- Paper PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. … DOI 10.1016/j.neo.2022.100793↗
- Yasunori Otowa · 3 shared papers, 2022–2024 · strength 0.54
- Paper Pharmacologic ascorbate induces transient hypoxia sensitizing pancreatic ductal adenocarcinoma to a hypoxia activated p… DOI 10.1016/j.freeradbiomed.2024.07.008↗
- Paper Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature an… DOI 10.1089/ars.2022.0118↗
- Paper PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. … DOI 10.1016/j.neo.2022.100793↗
- Tomohiro Seki · 3 shared papers, 2019–2022 · strength 0.32
- Paper PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. … DOI 10.1016/j.neo.2022.100793↗
- Paper Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and… DOI 10.1158/0008-5472.can-19-0928↗
- Paper Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. DOI 10.7554/elife.46312↗
- William Marston Linehan · 2 shared papers, 2019–2024 · strength 0.29
- Daniel R. Crooks · 2 shared papers, 2019–2024 · strength 0.29
- Mark N. Levine · 1 shared paper, 2024 · strength 0.22
- peter L choyke · 2 shared papers, 2019–2020 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.